{"nctId":"NCT00861757","briefTitle":"Multinational Study to Evaluate Tadalafil in Asian Men With Signs and Symptoms of Benign Prostatic Hyperplasia","startDateStruct":{"date":"2009-03"},"conditions":["Benign Prostatic Hyperplasia"],"count":612,"armGroups":[{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"2.5 mg Tadalafil","type":"EXPERIMENTAL","interventionNames":["Drug: Tadalafil"]},{"label":"5.0 mg Tadalafil","type":"EXPERIMENTAL","interventionNames":["Drug: Tadalafil"]},{"label":"0.2 mg Tamsulosin","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Tamsulosin"]}],"interventions":[{"name":"Tadalafil","otherNames":["LY450190, Cialis"]},{"name":"Placebo","otherNames":[]},{"name":"Tamsulosin","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Asian males, with benign prostatic hyperplasia (BPH) for at least 6 months prior to initiation and IPSS score greater than or equal to 13 at the beginning of the treatment\n* Agree not to use any other approved or experimental pharmacologic BPH, erectile dysfunction (ED) and overactive bladder (OAB) treatments at any time during the study.\n* Have not taken Finasteride or Dutasteride therapy, Anti-androgenic hormone or any other BPH therapy, ED or OAB therapy for specified duration of time prior to the beginning of the treatment\n\nExclusion Criteria:\n\n* Prostate specific antigen (PSA) score beyond acceptable range defined for study at initiation\n* History of urinary retention or lower urinary tract (bladder) stones within 6 months of initiation\n* History of urinary urethral obstruction due to stricture, valves, sclerosis, or tumor at initiation\n* Clinical evidence of prostate cancer at initiation\n* Clinical evidence of any of the bladder or urinary tract conditions, which may affect lower urinary tract symptom at initiation\n* History of cardiac conditions, including Angina requiring certain treatment with nitrates, unstable angina defined for study, positive cardiac stress test before starting the study\n* History of significant central nervous system injuries (including stroke or spinal cord injury within 6 months of initiation)\n* Use of any nitrates, cancer chemotherapy, androgens, antiandrogens, estrogens, luteinizing hormone-releasing hormone (LHRH)agonists/antagonists, or anabolic steroids at initiation","healthyVolunteers":false,"sex":"MALE","minimumAge":"45 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in International Prostate Symptom Score (IPSS) at 12 Weeks","description":"The IPSS Total Score is obtained by combining the scores of the responses to 1 through 7 component questions. Each question is scored from 0-5 for an IPSS range of 0-35 points; higher numerical scores from the IPSS questionnaire represent greater severity of symptoms.\n\nLeast Squares Mean values were controlled for prior alpha blocker use (yes/no), country (Japan/Korea/Taiwan) and baseline value.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.0","spread":"0.4"},{"groupId":"OG001","value":"-4.8","spread":"0.4"},{"groupId":"OG002","value":"-4.7","spread":"0.4"},{"groupId":"OG003","value":"-5.5","spread":"0.4"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to 12 Weeks in International Prostate Symptom Score (IPSS) Subscore (Storage [Irritative] and Voiding [Obstructive])","description":"IPSS obstructive subscore is the sum of Questions 1, 3, 5 and 6 of the IPSS questionnaire. Scores range from 0 (few obstructive symptoms) to 5 (frequent obstructive symptoms); 4 questions of the obstructive score range from 0 to 20. IPSS irritative subscore is the sum of Questions 2, 4 and 7 of IPSS questionnaire. Scores range from 0 (no irritative symptoms) to 5 (frequent irritative symptoms); 3 questions of the irritative subscore range from 0 to 15. Least Squares Mean values were controlled for prior alpha blocker use (yes/no), country (Japan/Korea/Taiwan), and baseline value.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.9","spread":"0.3"},{"groupId":"OG001","value":"-3.3","spread":"0.3"},{"groupId":"OG002","value":"-3.0","spread":"0.3"},{"groupId":"OG003","value":"-3.8","spread":"0.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.1","spread":"0.2"},{"groupId":"OG001","value":"-1.5","spread":"0.2"},{"groupId":"OG002","value":"-1.7","spread":"0.2"},{"groupId":"OG003","value":"-1.7","spread":"0.2"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in International Prostate Symptom Score (IPSS) Quality of Life (QoL) at 12 Weeks","description":"Assessment of QoL by urinary symptoms, with scores ranging from 0 (delighted) to 6 (terrible).\n\nLeast Squares Mean values were controlled for Benign Prostatic Hyperplasia severity (moderate/severe), prior alpha blocker use (yes/no), country (Japan/Korea/Taiwan), and baseline value.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":"0.1"},{"groupId":"OG001","value":"-0.8","spread":"0.1"},{"groupId":"OG002","value":"-0.8","spread":"0.1"},{"groupId":"OG003","value":"-1.1","spread":"0.1"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Benign Prostatic Hyperplasia (PBH) Impact Index (BII) at 12 Weeks","description":"The BII is a 4-item, self-administered questionnaire evaluating impact of urinary problems on overall health and activity. Total scores range from 0 to 13; higher scores represent increased perceived impact of benign prostatic hyperplasia-lower urinary tract symptoms on overall health. Least Squares Mean values were controlled for BPH severity (moderate/severe), prior alpha blocker use (yes/no), country (Japan/Korea/Taiwan) and baseline value.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.8","spread":"0.2"},{"groupId":"OG001","value":"-1.1","spread":"0.2"},{"groupId":"OG002","value":"-1.0","spread":"0.2"},{"groupId":"OG003","value":"-1.6","spread":"0.2"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Uroflowmetry Parameter: Peak Flow Rate (Qmax) at 12 Weeks","description":"Qmax: defined as the peak urine flow rate (measured in milliliters per second \\[mL/second\\] using standard calibrated flowmeter).\n\nLeast Squares Mean values were controlled for Benign Prostatic Hyperplasia (BPH) severity (moderate/severe), prior alpha blocker use (yes/no), country (Japan/Korea/Taiwan), and baseline value.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.1","spread":"0.4"},{"groupId":"OG001","value":"1.6","spread":"0.4"},{"groupId":"OG002","value":"1.3","spread":"0.4"},{"groupId":"OG003","value":"2.1","spread":"0.4"}]}]}]},{"type":"SECONDARY","title":"Patient Global Impression of Improvement (PGI-I) at Week 12","description":"The PGI-I measures the patient's perception of improvement at the time of assessment compared with the start of treatment. There are 7 categories with scores ranging from 1 (very much better) to 7 (very much worse). The data are presented as the number of participants in each of the 7 categories: very much better (1); much better (2); a little better (3); no change (4); a little worse (5); much worse (6); very much worse (7).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"5","spread":null},{"groupId":"OG003","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45","spread":null},{"groupId":"OG001","value":"26","spread":null},{"groupId":"OG002","value":"23","spread":null},{"groupId":"OG003","value":"25","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"54","spread":null},{"groupId":"OG001","value":"62","spread":null},{"groupId":"OG002","value":"74","spread":null},{"groupId":"OG003","value":"58","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32","spread":null},{"groupId":"OG001","value":"44","spread":null},{"groupId":"OG002","value":"40","spread":null},{"groupId":"OG003","value":"53","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"9","spread":null},{"groupId":"OG002","value":"10","spread":null},{"groupId":"OG003","value":"9","spread":null}]}]}]},{"type":"SECONDARY","title":"Clinician Global Impression of Improvement (CGI-I) at Week 12","description":"The CGI-I measures clinician's perception of patient improvement at the time of assessment compared with the start of treatment. There are 7 categories with scores ranging from 1 (very much better) to 7 (very much worse). The data are presented as the number of participants in each of the 7 categories: very much better (1); much better (2); a little better (3); no change (4); a little worse (5); much worse (6); very much worse (7).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"3","spread":null},{"groupId":"OG003","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44","spread":null},{"groupId":"OG001","value":"21","spread":null},{"groupId":"OG002","value":"29","spread":null},{"groupId":"OG003","value":"19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60","spread":null},{"groupId":"OG001","value":"67","spread":null},{"groupId":"OG002","value":"62","spread":null},{"groupId":"OG003","value":"68","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30","spread":null},{"groupId":"OG001","value":"39","spread":null},{"groupId":"OG002","value":"48","spread":null},{"groupId":"OG003","value":"47","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"11","spread":null},{"groupId":"OG002","value":"10","spread":null},{"groupId":"OG003","value":"12","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Prostate Specific Antigen (PSA) at 12 Weeks","description":"Nanograms of PSA per milliliter (ng/mL) of blood.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.03","spread":"0.55"},{"groupId":"OG001","value":"0.04","spread":"0.54"},{"groupId":"OG002","value":"0.13","spread":"0.59"},{"groupId":"OG003","value":"-0.06","spread":"0.61"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Postvoid Residual Volume (PVR) at 12 Weeks","description":"The PVR is defined as the volume of urine remaining in the bladder after voiding, estimated by ultrasound.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.20","spread":"45.35"},{"groupId":"OG001","value":"-0.09","spread":"45.21"},{"groupId":"OG002","value":"-2.90","spread":"48.84"},{"groupId":"OG003","value":"-5.67","spread":"34.38"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Blood Pressure (Sitting) at 12 Weeks","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":"10.9"},{"groupId":"OG001","value":"-2.3","spread":"11.0"},{"groupId":"OG002","value":"-0.5","spread":"12.4"},{"groupId":"OG003","value":"0.2","spread":"12.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"8.6"},{"groupId":"OG001","value":"-2.5","spread":"7.8"},{"groupId":"OG002","value":"-1.4","spread":"8.1"},{"groupId":"OG003","value":"-0.6","spread":"7.9"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Blood Pressure (Standing) at 12 Weeks","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":"11.8"},{"groupId":"OG001","value":"-2.9","spread":"12.3"},{"groupId":"OG002","value":"0.6","spread":"11.6"},{"groupId":"OG003","value":"-0.9","spread":"13.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"8.1"},{"groupId":"OG001","value":"-2.3","spread":"8.0"},{"groupId":"OG002","value":"-1.7","spread":"8.2"},{"groupId":"OG003","value":"-1.0","spread":"8.8"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Sitting Heart Rate (HR) at 12 Weeks","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"8.9"},{"groupId":"OG001","value":"0.7","spread":"8.3"},{"groupId":"OG002","value":"0.6","spread":"8.3"},{"groupId":"OG003","value":"0.6","spread":"7.8"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":154},"commonTop":["Nasopharyngitis","Myalgia","Headache","Back pain","Diarrhoea"]}}}